- Keen investor interest in its business and China growth strategy. Maintain BUY. TP lowered to SGD0.51, based on long-term mean of 39x FY15E fully-diluted EPS.
- Completed China acquisitions to boost profits significantly from 2H14. More acquisitions in the pipeline.
- Moving up value chain to fast-growing CAD/CAM dentistry, with Aidite’s aid.
We hosted Q&M to an NDR with 10 clients. Management reaffirmed that its completed acquisitions will boost profits significantly from 2H14E. Our current forecasts of SGD6.6m (+27% YoY) and SGD7.6m (+16%), which do not include contributions from acquisitions, would rise to SGD7.9m (+53%) in FY14E and SGD11m (+39%) in FY15E. Fully-diluted EPS, including the acquisitions, should grow 8% in FY14E and 39% in FY15E, their first full year of contributions.
Further M&A potential in China
Dr Ng, CEO of Q&M, shed more light on the private and public dental markets in China. We believe Q&M is pursuing more acquisitions in China. It can cherry-pick the best targets, as its acquisition of Aoxin has raised its profile in China’s dental industry.
Moving up the CAD/CAM value chain
Other than giving Q&M access to the China market and boosting its earnings via profit guarantees, Aidite should enable Q&M to participate more in CAD/CAM dentistry, the fastest-growing segment of dentistry. With its existing technology, 60 clinics in Singapore and now a source of reasonably-priced materials, Q&M now has the recipe for success in CAD/CAM dentistry services.
TP revised down to SGD0.51, 21% upside
We cut our TP to SGD0.51 (from SGD0.54) after assuming Heritas exercises its call option of 63m new shares in order to be entitled to the rights issue.
No comments:
Post a Comment